Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.

Cancer medicine·2025
Same author

Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.

Nature communications·2025
Same author

The Road From NIH Training Grants for Surgeons: What is the Return on Investment?

Annals of surgery·2025
Same author

PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer.

Cancer immunology, immunotherapy : CII·2025
Same author

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial.

JAMA dermatology·2025
Same author

Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical Trial.

JAMA oncology·2025

Related Experiment Video

Updated: Apr 28, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

23.9K

Remission in dermatitis herpetiformis: a cohort study.

So Yeon Paek1, Seth M Steinberg, Stephen I Katz

  • 1Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Archives of Dermatology
|November 17, 2010
PubMed
Summary

Dermatitis herpetiformis (DH) can achieve remission in some patients, with 12% experiencing disease remission. Later onset and earlier diagnosis years were associated with increased chances of DH remission.

More Related Videos

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

13.8K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

933

Related Experiment Videos

Last Updated: Apr 28, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

23.9K
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

13.8K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

933

Area of Science:

  • Immunodermatology
  • Gastroenterology

Background:

  • Dermatitis herpetiformis (DH) is a chronic autoimmune blistering skin disease.
  • It is characterized by granular IgA deposits at the dermoepidermal junction.
  • DH is strongly associated with celiac disease and gluten sensitivity.

Purpose of the Study:

  • To determine the remission rate of dermatitis herpetiformis (DH).
  • To identify factors associated with achieving DH remission.
  • To inform long-term management strategies for DH patients.

Main Methods:

  • Retrospective cohort study at the National Institutes of Health (NIH).
  • Included 86 patients diagnosed with DH between 1972 and 2010.
  • Remission defined as >2 years without lesions or symptoms, off specific medications and gluten-free diet.

Main Results:

  • 12% (10 of 86 patients) achieved DH remission.
  • Remission was associated with later age of onset (≥39 years).
  • Earlier onset year (1960-1972) was also linked to remission.

Conclusions:

  • Dermatitis herpetiformis (DH) can achieve remission.
  • Clinicians should consider trials of medication and diet weaning to assess for DH remission.
  • Findings offer insights into DH pathogenesis and guide patient management.